[ad_1]
Good Monday, Pfizer asked the US Food and Drug Administration for emergency authorization for the drugmaker’s new Omicron booster targeting the BA.4 and BA.5 strains. modern followed on Tuesday with its own application to the FDA for emergency authorization for its BA.5 booster.
But unlike previous applications, Pfizer and Moderna’s filings are missing one piece of information: clinical trial data of their vaccines.
That’s deliberate. In June, the FDA asked vaccine manufacturers to start developing BA.4 and BA.5 boosters for a fall vaccination campaign. To help the drugmakers hit that fall deadline, the FDA said the companies did not need to include data from a clinical trial.
“It’s very similar to what we do with influenza strain changes where there will be a couple of amino acids difference,” Dr. Peter Marks, who helps oversee vaccines for the FDA, told Reuters in late June. “We don’t expect any difference in the safety that we’re going to see,” he said.
Pfizer and Moderna’s applications this week still include important data, such as data on how earlier Omicron boosters in development performed against previous strains, as well as pre-clinical data for the BA.5 booster.
Pre-clinical trials are conducted in human cell cultures or in animals, and are used to test a drug’s effectiveness and safety. After that, the drug proceeds to clinical trials, in which it is administered to human subjects. Previous clinical trials of COVID vaccines took months to completesignificantly faster than the years it takes to complete a clinical trial for most drugs.
Pfizer and Moderna’s Omicron booster filings do not include the clinical trial data included in earlier vaccine applications. Moderna said a clinical trial of its BA.5 booster is currently under waywhile Pfizer said its trial is expected to start this month.
The FDA’s new exemption is an effort to speed up the approval process so updated COVID vaccines can keep pace with new variants, which are emerging so rapidly they risk making boosters out-of-date by the time the jabs reach the market. Both Pfizer and Moderna have been working on boosters that target BA.1—the original Omicron strain—since the beginning of the year. The UK approved vaccines that target BA.1 last week. But BA.1 has disappeared from the US, outcompeted by newer Omicron strains like BA.4 and BA.5. The latter now make up 88.9% of cases in the US, according to the US Centers for Disease Control and Prevention, up from 2.5% just three months ago.
And there are already new variants of concern emerging in the US and elsewhere. While BA.5 is by far the most dominant strain in the US, both BA.4.6 and BA.2.7.5 have managed to gain ground, pushing out other strains. Experts are now urging the development of a universal vaccine that can protect against current and future strains of the COVID-19 virus.
For now, a faster process “will help us get ahead of things,” said Marks to Reuters in June. But some experts criticize the FDA’s change, fearing that pre-clinical studies might not give a good indication of how effective a vaccine is in humans.
On Monday, Pfizer said that its booster would be available to ship “immediately” once the FDA approves it. Moderna said on Tuesday that it expects to have boosters ready by September.
But health experts recommend that those eligible for a second booster should get one now, rather than wait for updated boosters to be available.
Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.
[ad_2]
Source link
